TRECONY: Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (clinicaltrials.gov) - Apr 12, 2026 - P2 | N=250 | Recruiting | Sponsor: Chiesi Farmaceutici S.p.A. | N=165 ➔ 250
Enrollment change • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
|